## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

 (Currently Amended) A method of effectively treating nephritis, comprising: selecting an animal in need of treatment for nephritis; and administering to said animal a therapeutically effective dose of a neutralizing antibody, or binding fragment thereof, that binds to platelet derived growth factor-DD (PDGF-DD),

wherein said neutralizing antibody, or binding fragment thereof, neutralizes PDGF-DDinduced mitogenic activity, and wherein said neutralizing antibody, or binding fragment thereof, comprises fully human anti-PDGF-DD antibody mAb 6.4 monoclonal antibody having variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:2 and a variable region of the light chain consisting of the amino acid sequence of SEO ID NO:4 or an antibody in the same antigen-binding bin as fully human anti-PDGF-DD antibody mAb-6.4 having a variable region of the heavy chain consisting of the amino acid sequence of SEO ID NO:2 and a variable region of the light chain consisting of the amino acid sequence of SEO ID NO:4, wherein said antibody in the same antigen-binding bin is selected from a fully human antibody mAb 1.9, 1.19, 1.22, and 1.29 having a variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:22 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:24, and a fully human antibody having a variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:38 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:40, and wherein said nephritis is selected from mesangial proliferative nephritis, mesangial proliferative glomerulonephritis and glomerular nephritis.

- 2. (Original) The method of claim 1, wherein said animal is a human.
- 3. (Previously Presented) The method of claim 1, wherein said neutralizing antibody is a fully human monoclonal antibody.
- 4. 5. (Cancelled)

Applicant: Floege et al. U.S.S.N. 10/665,383

- 6. (Original) The method of claim 1, wherein said administration is via subcutaneous injection.
- 7. (Original) The method of claim 1, wherein said administration is via intramuscular injection.
- 8. 21. (Cancelled)
- 22. (Previously Presented) The method of claim 1, wherein said neutralizing antibody has a Kd in the range of about 10<sup>-6</sup> to 10<sup>-11</sup> M as measured in either solid phase or solution phase.
- 23. (Previously Presented) The method of claim 1, wherein said neutralizing antibody comprises a fully human IgG2 heavy chain.
- 24. (Previously Presented) The method of claim 1, wherein said neutralizing antibody comprises a fully human IgG2 heavy chain and a human kappa light chain.
- 25. (Currently Amended) A method of effectively treating nephritis, comprising: selecting an animal in need of treatment for nephritis; and administering to said animal a therapeutically effective dose of a neutralizing antibody, or binding fragment thereof, that binds to platelet derived growth factor-DD (PDGF-DD),

wherein said neutralizing antibody, or binding fragment thereof, neutralizes PDGF-DD-induced mitogenic activity, and wherein said neutralizing antibody, or binding fragment thereof comprises fully human anti-PDGF-DD antibody mAb 6.4 monoclonal antibody having a variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:2 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:4 or an antibody in the same antigen-binding bin as fully human anti-PDGF-DD antibody mAb 6.4 having a variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:2 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:4, wherein said antibody in the same antigen-binding bin is selected from a fully human antibody mAb 1.9, 1.19, 1.22, and 1.29 having a variable region of the heavy chain consisting of the amino acid sequence of SEQ ID NO:22 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:24, and a fully human antibody having a variable region of the heavy chain

Applicant: Floege *et al.* U.S.S.N. 10/665,383

consisting of the amino acid sequence of SEQ ID NO:38 and a variable region of the light chain consisting of the amino acid sequence of SEQ ID NO:40 and wherein said neutralizing antibody, or binding fragment thereof, comprises a fully human IgG2 heavy chain, and wherein said nephritis is selected from mesangial proliferative nephritis, mesangial proliferative glomerulonephritis and glomerular nephritis.

- 26. (Currently Amended) The method of claim 25, wherein the light chain of said neutralizing antibody further comprises is a human kappa light chain.
- 27. (Previously Presented) The method of claim 25, wherein said animal is a human.
- 28. (Previously Presented) The method of claim 25, wherein said neutralizing antibody is a fully human monoclonal antibody.
- 29. 30. (Cancelled)
- 31. (Previously Presented) The method of claim 25, wherein said administration is via subcutaneous injection.
- 32. (Previously Presented) The method of claim 25, wherein said administration is via intramuscular injection.
- 33. (Previously Presented) The method of claim 25, wherein said neutralizing antibody has a Kd in the range of about 10<sup>-6</sup> to 10<sup>-11</sup> M as measured in either solid phase or solution phase.